Boston Scientific (NYSE:BSX) Rating Lowered to “Market Perform” at Oppenheimer

Boston Scientific (NYSE:BSX) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued on Thursday, MarketBeat reports.

BSX has been the subject of several other research reports. Needham & Company LLC dropped their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday. BTIG Research reduced their price target on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. Jefferies Financial Group lowered Boston Scientific from a “buy” rating to a “hold” rating and set a $46.00 price target on the stock. in a research report on Wednesday. Piper Sandler decreased their price objective on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, July 29th. Finally, Citigroup reduced their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.77.

Boston Scientific Stock Down 6.6%

Shares of NYSE BSX opened at $42.09 on Thursday. The firm has a market capitalization of $61.00 billion, a PE ratio of 17.04, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific has a 1 year low of $39.57 and a 1 year high of $105.65. The firm’s 50-day moving average is $45.12 and its 200-day moving average is $57.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.07 billion. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. Equities analysts expect that Boston Scientific will post 3.21 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter worth $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $2,156,233,000. Jupiter Topco LLC bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $803,357,000. Bank of America Corp DE acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $556,026,000. Finally, Legal & General Group Plc acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $431,890,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue rose 1.5% to $5.138 billion, exceeding analysts’ $5.07 billion estimate, while adjusted EPS of $0.73 matched expectations. Management also reaffirmed its long-term growth strategy and highlighted progress in clinical programs and FDA clearances. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management expects approximately 4% organic revenue growth for full-year 2026 and is targeting a recovery cycle after anticipated 2027 weakness, followed by expansion toward 2030. Recent insider activity also showed purchases rather than sales, including a substantial purchase by CEO Michael Mahoney. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Needham lowered its price target from $57 to $48 but maintained a Buy rating, while JPMorgan downgraded BSX from Overweight to Neutral and set a $46 target. The revised targets remain above the stock’s recent trading level but reflect reduced confidence in the near-term outlook.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations, customer activity, and the recovery timeline. Boston Scientific cut its full-year EPS outlook to $3.16–$3.18 and expects fourth-quarter reported and organic sales to decline 1%–3%. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand, pricing pressure in China, and management’s warning that 2027 could be difficult. GAAP EPS fell to $0.40 from $0.51 a year earlier, and the stock has traded near a four-year low.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.